Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies

Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.